Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04603521 · ClinicalTrials.gov registry record
Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
A clinical trial of Cardiomyopathy and Obstructive Hypertrophic Cardiomyopathy, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 325
- Enrollment target
- 1
- Study location
NCT04603521: Completed study of Cardiomyopathy and Obstructive Hypertrophic Cardiomyopathy, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT04603521 is a study of Cardiomyopathy and Obstructive Hypertrophic Cardiomyopathy that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 325 participants, below the 544-participant average among 25 other Cardiomyopathy trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04603521, a study of Cardiomyopathy and Obstructive Hypertrophic Cardiomyopathy, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 325 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: HCM is a genetic heart disease. It can cause fatigue, chest pain, or even death. For more than 50 years, a surgery called septal myectomy has been used to help people with this disease. Dr. Andrew G. Morrow originated the surgery and performed it more than 200 times at NIH starting in 1960. Researchers want to learn the long-term success of this surgery. Objective: To determine long-term survival at least 35 years after surgical myectomy at NIH and examine data for people who are confirmed to be deceased or alive. Eligibility: People who had surgical myectomy by Dr. Morrow from 1960 to 1983. Design: This study uses images and data that were obtained in the past. Many of the participants are deceased. Most of the others are no longer being followed at the NIH. The medical records of people treated by Dr. Morrow were microfiched. These records can be accessed at the NIH. The records will be searched for keywords to find participants for this study. Participants clinical data, such as lab testing and imaging, will be used. Other data collected as part of the original study will also be used. Researchers will use participants name, date of birth, and Social Security number to learn if they are alive or deceased. If they are deceased, researchers will try to find the age of death. Online databases and search engines will also be used. Survival data will be compared to data from the general U.S. population for the same time period. Data will be stored in a database that is password protected. The study will last about 1 year.
Primary Outcome
To determine long-term survival at least 35 years after surgical myectomy at NIH. To examine survival data in those subjects in whom we can confirm a date of death or an indication that they are still alive.
Conditions Studied
Study Locations (1)
Maryland
- National Heart, Lung and Blood Institute (NHLBI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2020-10-20 |
| Est. Completion | 2022-04-26 |
What the finished NCT04603521 record still lists
NCT04603521 is an observational study that tracks outcomes without assigning an intervention. The registered 325 participants enrollment target is mid-sized for trials with a published cap, below the 544-participant average among 25 other Cardiomyopathy trials with a reported enrollment target (40% lower).
The record links to 2 conditions, with Cardiomyopathy appearing as the primary indexed condition, and to 0 interventions.
NCT04603521 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04603521 about?
NCT04603521 is a clinical study titled "Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)". Background: HCM is a genetic heart disease. It can cause fatigue, chest pain, or even death. For more than 50 years, a surgery called septal myectomy has been used to help people with this disease. Dr. Andrew G. Morrow originated the surgery and performed it more than 200 times at NIH starting in 1...
What is the current status of trial NCT04603521?
This trial is currently completed. The enrollment target is 325 participants. The study started on 2020-10-20. Estimated completion is 2022-04-26.
What conditions does trial NCT04603521 study?
This clinical trial studies the following conditions: Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy.
Who is sponsoring clinical trial NCT04603521?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04603521 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04603521's enrollment target sits among peer trials
325 8th of 25 higher than 18 of 25 other Cardiomyopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiomyopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
RECRUITING
-
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
RECRUITING · Phase 4
-
Molecular Imaging of Primary Amyloid Cardiomyopathy
RECRUITING · NA
-
Impella Reverse Remodeling in End-Stage Heart Failure
RECRUITING
-
Clinical Course Of Disease In Participants With FA-CM
RECRUITING
-
Genetics of Cardiovascular and Neuromuscular Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02543983 · 325 participants · Phase 2
Neurobiology of Suicide
- NCT03016819 · 325 participants · Phase 3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- NCT03288207 · 325 participants · NA
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
- NCT04986657 · 325 participants · NA
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI